These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 23053257)

  • 1. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
    Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
    JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
    Jiang WZ; Guan GX; Lu HS; Yang YH; Kang DY; Huang HG
    J Surg Oncol; 2011 Dec; 104(7):760-4. PubMed ID: 21713778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
    Kang HJ; Ryu MH; Kim KM; Park YS; Choi J; Ryoo BY; Kim WH; Im SA; Bang YJ; Park SH; Lee JH; Chung IJ; Bae HI; Kim JG; Lee KH; Song HS; Kwon HC; Baek JH; Shin DB; Lee KE; Kang YK
    Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
    Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
    Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
    Li J; Dang YZ; Gao J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):216-20. PubMed ID: 23536338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient with high-risk GIST not associated with c-KIT mutations: same benefit from adjuvant therapy?
    Izquierdo ME; Bonastre MT
    Anticancer Drugs; 2012 Jun; 23 Suppl():S7-9. PubMed ID: 22739668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
    López RL; del Muro XG
    Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
    Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use.
    Koh Y; Lee HE; Oh DY; Kim JH; Lee SH; Kim SH; Kim DW; Im SA; Kim TY; Heo DS; Kim WH; Bang YJ
    Jpn J Clin Oncol; 2012 Nov; 42(11):1020-7. PubMed ID: 22952296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
    Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
    Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
    Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
    Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
    J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
    Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
    Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH
    Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
    J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial].
    Zhan WH; Wang PZ; Shao YF; Wu XT; Gu J; Li R; Wan DS; Ding KF; Shi YQ; Yu JR; Lu HS; Zou XM; Bi JW; Sun YH; Lu YF; Chen DD; Zhang XH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Sep; 9(5):383-7. PubMed ID: 17043955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour.
    Gronchi A
    Eur J Cancer; 2013 Mar; 49(4):884-92. PubMed ID: 23206668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.